Answer:
variable expressivity; incomplete penetrance
Explanation:
In genetics, variable expressivity refers to the fact that individuals having the same alleles/genes/genotype associated with a particular genetic condition may exhibit different clinical features of this condition. In general, variable expressivity is due to the combination of both genetic and environmental factors. An example of variable expressivity is the Marfan syndrome, where all individuals with this disorder have a dominant mutation in the FBN1 (fibrillin 1) gene and show different degrees of the same phenotype. Moreover, incomplete penetrance (also known as reduced penetrance) refers to the complete absence of a genetic trait or disease in individuals having alleles/genes/genotype associated with the condition. In consequence, individuals with incomplete penetrance do not develop features of the disease. An example of incomplete penetrance is given by those individuals with mutations in BRCA1/BRCA2 genes (associated with an increased risk of developing breast cancer) that do not develop cancer.
Answer:
Explanation:
Synovial joints, often referred to as joints, are composed of two or more bones with a gap between the opposite bone surfaces, connected only by the fibrous connective tissue membrane around them. The synovial joint is the main form of bone joint and has great mobility.
<em>The preclinical trial of therapy against Alzheimer’s disease (AD) is an essential and complex step. It functions as a bridge between candidate discovery and clinical development since it constantly provides us with new information on pieces of the complex AD puzzle. Analysis of this information is likely to reveal patterns of pharmacological interactions instead of the single potential drug target. A group of well-trained, knowledgeable medicinal biochemists in Alzheimacy with decades of experience in preclinical research are willing to work with leaders and scientists from academia, pharmaceutical and biotechnology companies around the world to further develop more promising and stringent therapeutics for AD.</em>
<em>https://www.creativebiomart.net/alzheimacy/solutions/preclinical-development/</em>
Copper and tin together make bronze.
